Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1716 ARTÍCULOS , VIENDO DEL 1381 AL 1395

Inter-individual differences in the responses to aerobic exercise in Alzheimer's disease: Findings from the FIT-AD trial

Yu F, Salisbury D, Mathiason MA.

J Sport Health Sci. 2021 Jan;10(1):65-72. doi: 10.1016/j.jshs.2020.05.007. Epub 2020 Jun 4.

Modelling neurodegenerative disease using brain organoids

Wray S.

Semin Cell Dev Biol. 2021 Mar;111:60-66. doi: 10.1016/j.semcdb.2020.05.012. Epub 2020 Jun 5.

Autophagic Pathways to Clear the Tau Aggregates in Alzheimer's Disease

Gorantla NV, Chinnathambi S.

Cell Mol Neurobiol. 2021 Aug;41(6):1175-1181. doi: 10.1007/s10571-020-00897-0. Epub 2020 Jun 11.

From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology

Albertini C, Salerno A, de Sena Murteira Pinheiro P, Bolognesi ML.

Med Res Rev. 2021 Sep;41(5):2606-2633. doi: 10.1002/med.21699. Epub 2020 Jun 19.

Insights into lncRNAs in Alzheimer's disease mechanisms

Li D, Zhang J, Li X, Chen Y, Yu F, Liu Q.

RNA Biol. 2021 Jul;18(7):1037-1047. doi: 10.1080/15476286.2020.1788848. Epub 2020 Jul 14.

D-Glucose uptake and clearance in the tauopathy Alzheimer's disease mouse brain detected by on-resonance variable delay multiple pulse MRI

Chen L, Wei Z, Chan KW, Li Y, Suchal K, Bi S, Huang J, Xu X, Wong PC, Lu H, van Zijl PC, Li T, Xu J.

J Cereb Blood Flow Metab. 2021 May;41(5):1013-1025. doi: 10.1177/0271678X20941264. Epub 2020 Jul 16.

Mitochondria as a promising target for developing novel agents for treating Alzheimer's disease

Shevtsova EF, Maltsev AV, Vinogradova DV, Shevtsov PN, Bachurin SO.

Med Res Rev. 2021 Mar;41(2):803-827. doi: 10.1002/med.21715. Epub 2020 Jul 20.

Methylenetetrahydrofolate reductase C667T polymorphism and susceptibility to late-onset Alzheimer's disease in the Italian population

Zuin M, Cervellati C, Trentini A, Roncon L, Guasti P, Zuliani G.

Minerva Med. 2021 Jun;112(3):365-371. doi: 10.23736/S0026-4806.20.06801-9. Epub 2020 Jul 22.

Neurobiological Targets of Apathy Can Guide Treatment Development

Alexopoulos GS.

Am J Geriatr Psychiatry. 2021 Jan;29(1):63-65. doi: 10.1016/j.jagp.2020.06.023. Epub 2020 Jun 30.

The Mechanistic Role of Bridging Integrator 1 (BIN1) in Alzheimer's Disease

Gao P, Ye L, Cheng H, Li H.

Cell Mol Neurobiol. 2021 Oct;41(7):1431-1440. doi: 10.1007/s10571-020-00926-y. Epub 2020 Jul 27.

Parvalbumin interneuron vulnerability and brain disorders

Ruden JB, Dugan LL, Konradi C.

Neuropsychopharmacology. 2021 Jan;46(2):279-287. doi: 10.1038/s41386-020-0778-9. Epub 2020 Jul 28.

Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort

Abdeljalil AB, de Mauléon A, Baziard M, Vellas B, Lapeyre-Mestre M, Soto M.

J Am Med Dir Assoc. 2021 Feb;22(2):433-439. doi: 10.1016/j.jamda.2020.06.028. Epub 2020 Jul 28.

A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

Gadhave K, Kumar D, Uversky VN, Giri R.

Med Res Rev. 2021 Sep;41(5):2689-2745. doi: 10.1002/med.21719. Epub 2020 Aug 11.

Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Blood-Brain Barrier for Effective Treatment of Alzheimer's Disease

Arora S, Layek B, Singh J.

Mol Pharm. 2021 Feb 1;18(2):714-725. doi: 10.1021/acs.molpharmaceut.0c00461. Epub 2020 Sep 16.

Expanded access: opening doors to personalized medicine for rare disease patients and patients with neurodegenerative diseases

Özdinler PH.

FEBS J. 2021 Mar;288(5):1457-1461. doi: 10.1111/febs.15529. Epub 2020 Sep 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias